- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Pasithea Therapeutics Corp (KTTA)
Pasithea Therapeutics Corp stock price live, this page displays NASDAQ KTTA stock exchange data. View the KTTA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Pasithea Therapeutics Corp real time stock price chart below.
What Is the Pasithea Therapeutics Corp Stock Price Today?
The Pasithea Therapeutics Corp stock price today is 0.500.
What Is the Stock Symbol for Pasithea Therapeutics Corp?
The stock symbol for Pasithea Therapeutics Corp is "KTTA."
What Stock Exchange Does Pasithea Therapeutics Corp Trade On?
Pasithea Therapeutics Corp is listed and trades on the NASDAQ stock exchange.
Is Pasithea Therapeutics Corp a Good Stock to Buy?
Determining whether Pasithea Therapeutics Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the KTTA quote. (ISIN: US70261F2020)
What Is the Pasithea Therapeutics Corp Stock Price Today?
The Pasithea Therapeutics Corp stock price today is 0.500.
What Is the Stock Symbol for Pasithea Therapeutics Corp?
The stock symbol for Pasithea Therapeutics Corp is "KTTA."
What Stock Exchange Does Pasithea Therapeutics Corp Trade On?
Pasithea Therapeutics Corp is listed and trades on the NASDAQ stock exchange.
Is Pasithea Therapeutics Corp a Good Stock to Buy?
Determining whether Pasithea Therapeutics Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the KTTA quote. (ISIN: US70261F2020)
NASDAQ
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.491
0.519
52 wk Range
0.281
2.060
Unusual Pre-Market activity
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.4910.519
52 wk Range
0.2812.060
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
KTTA Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
3.000
Upside
+500.00%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock has taken a big hit over the last week
- Form 13G Pasithea Therapeutics Corp. For: 23 June
- Investing.com
- Form 13G Pasithea Therapeutics Corp. For: 23 June
- Investing.com
- Form 4 Pasithea Therapeutics Corp For: 22 June
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 3.000
(+500.00% Upside)
Earnings
Latest Release
Jun 03, 2026
EPS / Forecast
-0.12 / --
Revenue / Forecast
-- / --
Compare KTTA to Peers and Sector
Metrics to compare | KTTA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipKTTAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.8x | −7.4x | −0.4x | |
PEG Ratio | −0.01 | 0.66 | 0.00 | |
Price/Book | 0.3x | 4.4x | 2.6x | |
Price / LTM Sales | - | 20.8x | 3.0x | |
Upside (Analyst Target) | - | 210.6% | 51.9% | |
Fair Value Upside | Unlock | −6.6% | 9.1% | Unlock |
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company’s lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Pasithea Therapeutics (KTTA) Stock Price Today?
The Pasithea Therapeutics stock price today is 0.500 USD.
What Stock Exchange Does Pasithea Therapeutics Trade On?
Pasithea Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Pasithea Therapeutics?
The stock symbol for Pasithea Therapeutics is "KTTA."
What Is the Pasithea Therapeutics Market Cap?
As of today, Pasithea Therapeutics market cap is 16.710M USD.
What Is Pasithea Therapeutics's Earnings Per Share (TTM)?
The Pasithea Therapeutics EPS (TTM) is -1.571.
When Is the Next Pasithea Therapeutics Earnings Date?
Pasithea Therapeutics will release its next earnings report on Sep 02, 2026.
From a Technical Analysis Perspective, Is KTTA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Pasithea Therapeutics Stock Split?
Pasithea Therapeutics has split 1 times.
How Many Employees Does Pasithea Therapeutics Have?
Pasithea Therapeutics has 5 employees.
What is the current trading status of Pasithea Therapeutics (KTTA)?
As of Jul 10, 2026, Pasithea Therapeutics (KTTA) is trading at a price of 0.500 USD, with a previous close of 0.500 USD. The stock has fluctuated within a day range of 0.491 USD to 0.519 USD, while its 52-week range spans from 0.281 USD to 2.060 USD.
What Is Pasithea Therapeutics (KTTA) Price Target According to Analysts?
The average 12-month price target for Pasithea Therapeutics is 3.000 USD, with a high estimate of 3 USD and a low estimate of 3 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +500.00% Upside potential.
What Is the KTTA Premarket Price?
KTTA's last pre-market stock price is 0.526 USD. The pre-market share volume is 355.000, and the stock has decreased by 0.026, or 5.200%.
What Is the KTTA After Hours Price?
KTTA's last after hours stock price is 0.520 USD, the stock has decreased by 0.020, or 4.000%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.